These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 27900668)

  • 21. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
    Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study.
    Sjögren V; Byström B; Renlund H; Svensson PJ; Oldgren J; Norrving B; Själander A
    PLoS One; 2017; 12(7):e0181000. PubMed ID: 28700711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
    Larsen TB; Gorst-Rasmussen A; Rasmussen LH; Skjøth F; Rosenzweig M; Lip GY
    Am J Med; 2014 Jul; 127(7):650-656.e5. PubMed ID: 24530792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
    Larsen TB; Rasmussen LH; Gorst-Rasmussen A; Skjøth F; Lane DA; Lip GY
    Am J Med; 2014 Dec; 127(12):1172-8.e5. PubMed ID: 25193361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Propensity score methods for comparative-effectiveness analysis: A case study of direct oral anticoagulants in the atrial fibrillation population.
    Ciminata G; Geue C; Wu O; Deidda M; Kreif N; Langhorne P
    PLoS One; 2022; 17(1):e0262293. PubMed ID: 35073380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.
    Lip GY; Pan X; Kamble S; Kawabata H; Mardekian J; Masseria C; Bruno A; Phatak H
    Int J Clin Pract; 2016 Sep; 70(9):752-63. PubMed ID: 27550177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
    Noseworthy PA; Yao X; Abraham NS; Sangaralingham LR; McBane RD; Shah ND
    Chest; 2016 Dec; 150(6):1302-1312. PubMed ID: 27938741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.
    Goldhaber SZ; Schulman S; Eriksson H; Feuring M; Fraessdorf M; Kreuzer J; Schüler E; Schellong S; Kakkar A
    Thromb Haemost; 2017 Nov; 117(11):2045-2052. PubMed ID: 29202209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bleeding events with dabigatran or warfarin in patients with venous thromboembolism.
    Majeed A; Goldhaber SZ; Kakkar A; Kearon C; Eriksson H; Kreuzer J; Feuring M; Hantel S; Friedman J; Schellong S; Schulman S
    Thromb Haemost; 2016 Jan; 115(2):291-8. PubMed ID: 26403199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation.
    Ezekowitz MD; Eikelboom J; Oldgren J; Reilly PA; Brueckmann M; Kent AP; Pogue J; Spahr J; Clemens A; Noack H; Diener HC; Wallentin L; Yusuf S; Connolly SJ
    Europace; 2016 Jul; 18(7):973-8. PubMed ID: 26944733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
    Schulman S; Kakkar AK; Goldhaber SZ; Schellong S; Eriksson H; Mismetti P; Christiansen AV; Friedman J; Le Maulf F; Peter N; Kearon C;
    Circulation; 2014 Feb; 129(7):764-72. PubMed ID: 24344086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation.
    Lau WC; Chan EW; Cheung CL; Sing CW; Man KK; Lip GY; Siu CW; Lam JK; Lee AC; Wong IC
    JAMA; 2017 Mar; 317(11):1151-1158. PubMed ID: 28324091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticoagulants Resumption after Warfarin-Related Intracerebral Haemorrhage: The Multicenter Study on Cerebral Hemorrhage in Italy (MUCH-Italy).
    Poli L; Grassi M; Zedde M; Marcheselli S; Silvestrelli G; Sessa M; Zini A; Paciaroni M; Azzini C; Gamba M; Toriello A; Tassi R; Giorli E; Calabrò RS; Ritelli M; De Vito A; Pugliese N; Martini G; Lanari A; Lodigiani C; Padroni M; De Giuli V; Caria F; Morotti A; Costa P; Strambo D; Corato M; Pascarella R; Del Sette M; Malferrari G; Colombi M; Padovani A; Pezzini A;
    Thromb Haemost; 2018 Mar; 118(3):572-580. PubMed ID: 29433151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world on-treatment and initial treatment absolute risk differences for dabigatran vs warfarin in older US adults.
    Webster-Clark M; Stürmer T; Edwards JK; Poole C; Simpson RJ; Lund JL
    Pharmacoepidemiol Drug Saf; 2020 Aug; 29(8):832-841. PubMed ID: 32666678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dabigatran etexilate: An alternative to warfarin for patients with nonvalvular atrial fibrillation.
    Scott KA; Amirehsani KA
    J Am Assoc Nurse Pract; 2015 Apr; 27(4):190-6. PubMed ID: 25066647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation.
    Jaffer IH; Stafford AR; Fredenburgh JC; Whitlock RP; Chan NC; Weitz JI
    J Am Heart Assoc; 2015 Aug; 4(8):e002322. PubMed ID: 26304938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
    Ali A; Bailey C; Abdelhafiz AH
    Age Ageing; 2012 Sep; 41(5):681-4. PubMed ID: 22378612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™.
    Goldhaber SZ; Eriksson H; Kakkar A; Schellong S; Feuring M; Fraessdorf M; Kreuzer J; Schueler E; Schulman S
    Vasc Med; 2016 Dec; 21(6):506-514. PubMed ID: 27807306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simulation for Predicting Effectiveness and Safety of New Cardiovascular Drugs in Routine Care Populations.
    Najafzadeh M; Schneeweiss S; Choudhry NK; Wang SV; Gagne JJ
    Clin Pharmacol Ther; 2018 Nov; 104(5):1008-1015. PubMed ID: 29424437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.